Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future res
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Shakti, LLC, today announced that it has changed its name ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... our transformation into a company focused on patent claim analysis ... validity." In ... the Company commenced a corporate re-branding initiative in order to ...
(Date:8/28/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... acquisition of leading OTC brands from GSK in an ... is a clear demonstration of Perrigo,s unique ability to ... network spanning 36 countries.  Perrigo Chairman, ... "We are excited to complete this transaction, which clearly ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 ... announced that its shareholders have approved Mylan,s proposed ... ; TASE) and the related issuance of Mylan ... general meeting of shareholders held today. The transaction ... the extraordinary general meeting. In addition, the transaction ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Prime Therapeutics, one of the nation,s leading pharmacy ... offering a complete spectrum of options from rich benefits ... comes with a net drug spend guarantee of $47 ... predictable for plan sponsors," said Michael Showalter, Prime Chief ...
... an Informa business unit, and the world,s leading research ... from the 14th International Conference on Alzheimer,s Disease (ICAD ... continues to develop beta amyloid targeting drugs, amyloid targets ... warning for risk of Alzheimer,s. According to ...
Cached Medicine Technology:Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription 2Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality 2
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and ... just $199, patients can currently receive a one hour treatment of this teeth whitening ... it includes a number of unique features that can turn teeth up to nine ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... announce its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil ... features revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... to distributing health information technology innovation to transform quality and efficiency of healthcare ... survey will be de-identified and aggregated before being publicly shared to document progress ...
(Date:8/28/2015)... DC (PRWEB) , ... August ... ... Information Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information ... CMS-backed alignment demonstration approved for a December 2015 launch; and Idaho’s partnership ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review site ... millionaire dating sites . According to the listings, MillionaireMatch.com bags the ... category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has been ...
Breaking Medicine News(10 mins):Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2
... TeamStaff, Inc.,(Nasdaq: TSTF ) a national provider of ... notified by the Nasdaq Stock,Market that the Nasdaq Hearings ... the Nasdaq Global Market pending the effectiveness of the,Company,s ... was held on February 7, 2008. The decision of ...
... mg Delivers the Same, Medicine at the Same Dose ... Nearly 30 Million Frequent ... Beginning early March 2008,the nearly 30 million frequent heartburn ... them as retailers begin selling store,brand Omeprazole, a proton ...
... CHAPEL HILL, N.C., March 12 R&D structure ... is,essential to pharmaceutical companies. In a competitive market ... process increases -- the need to have an,optimized ... Discover the best-suited organizational structure that promotes rapid,growth, ...
... Calif., March 12 Omnicell,Inc. (Nasdaq: OMCL ), ... announced today that it has completed its $40.0,million program ... of,2,133,898 shares were repurchased at an average price of ... OMCL ) is a leading provider of systems and,software ...
... part of its ongoing effort to,give consumers information ... announced that four area hospitals have been,selected as ... Blue Distinction(R) is a nationwide program created ... care decisions and to work with their,health care ...
... Plans Participation in 2009 Medicare Advantage Open Enrollment in ... Florida Upon Approval of Applications, ... (Pink Sheets: PHYH), a developer of,health maintenance organizations (HMOs) in ... applications for the launch,of its pilot HMO in the state ...
Cached Medicine News:Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 2Health News:Nasdaq Hearings Panel Grants TeamStaff's Request for Continued Listing Subject to a Reverse Stock Split 3Health News:First Over-The-Counter Store Brand Omeprazole Offering in U.S. Market Creates New Option for Frequent Heartburn Sufferers 2Health News:First Over-The-Counter Store Brand Omeprazole Offering in U.S. Market Creates New Option for Frequent Heartburn Sufferers 3Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Omnicell Announces Completion of Its Common Stock Repurchase Plan 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 3Health News:Phyhealth Submits HMO Applications with Required Federal and State Agencies 2Health News:Phyhealth Submits HMO Applications with Required Federal and State Agencies 3
The Stryker Shoulder Instrumentation Set is ideal for open and arthroscopic shoulder procedures. The kit includes all the necessary tools for bone and tissue preparation as well as suture management ...
... The Arthroscopy Scissor is ideal for excising soft ... debris in the joint. The serrated edge on ... well as hold tissue within the jaws for ... and right jaw curvatures, are the perfect tools ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
Medicine Products: